Cancer chemotherapy: A SN-38 (7-Ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug monoTherapy) strategy

Cancer chemotherapy: A SN-38 (7-Ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug monoTherapy) strategy Benzyl Ether-Linked Glucuronide Derivative of 10-Hydroxycamptothecin Designed for Selective Camptothecin-Based Anticancer Therapy Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT) 10-Boronic acid substituted camptothecin as prodrug of SN-38 Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy Synthesis and biological evaluation of novel SN38-glucose conjugate for colorectal cancer treatment Monodisperse oligoethylene glycols modified Camptothecin, 10-Hydroxycamptothecin and SN38 prodrugs Synthesis and biological evaluation of hypoxia-activated prodrugs of SN-38 Study of a cyclopamine glucuronide prodrug for the selective chemotherapy of glioblastoma Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) β-glucuronide and β-galactoside for application in selective prodrug chemotherapy